

4. A compound according to any one of claims 1 to 2 for use as therapeutically active substance.

5. A pharmaceutical composition comprising at least one of the compounds according to any one of claims 1 to 2 as well as its pharmaceutically acceptable salt.

5 6. A compound of any one of claims 1 to 2, when applicable as mixtures of enantiomers, diastereomers, or in enantiomerically pure form; as well as its pharmaceutically acceptable salt, for use as a medicament.

10 7. The use of a compound according to any one of claims 1 to 2 as well as its pharmaceutically acceptable salt for the manufacture of a medicament for the treatment or prevention of diseases relating to allosteric modulators of mGluR⁵ receptors.

8. The use of a compound according to claim 7 for the treatment or prevention of schizophrenia, cognitive diseases, fragile X syndrome or autism.

9. A compound according to any one of claims 1 to 2 for the treatment or prevention of schizophrenia, cognitive diseases, fragile X syndrome or autism.

15 10. A method for the treatment of schizophrenia, cognitive diseases, fragile X syndrome or autism, which method comprises administering an effective amount of a compound as defined in any one of claims 1 to 2.

11. The invention as hereinbefore described.